Long-Term Survival of a Patient with Invasive Signet-Ring Cell Carcinoma of the Urinary Bladder Managed by Combined S-1 and Cisplatin Adjuvant Chemotherapy

Table 1

Description of all cases of adjuvant chemotherapy regimens used in advanced SRCCU in Japan with more than 6-month followup.

Reference	Pathological T stage	Chemotherapy regimen	Followup
Tsumatani et al. [8]	pT3b	UFT, ADM, MMC, OK432	29 months
Amemiya et al. [9]	pT3b	UFT, CDDP, ADM, CPA	Died 12 months after diagnosis
Tukumo et al. [10]	pT4	CDDP, MTX, VP-16	Died 7 months after diagnosis
Nanpo et al. [11]	pT3a	5-FU, MTX	Died 8 months after diagnosis
Fujita et al. [12]	pT3a	S-1	8 months
Our case	pT3b	S-1, CDDP	90 months

OK432: Picibanil; 5-FU: 5-fluorouracil; CDDP: cisplatin; MTX: methotrexate; UFT: tegafur + uracil; VP-16: etoposide; ADM: adriamycin; CPA: cyclophosphamide; MMC: mitomycin C; S-1: tegafur-gimeracil-oteracil potassium.